12 Result(s)

Article

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines.

B Escudier, M D Michaelson, R J Motzer, T E Hutson, J I Clark… in British Journal of Cancer (2014)

Article

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in...

A Saroufim, Y Messai, M Hasmim, N Rioux, R Iacovelli… in British Journal of Cancer (2014)

Article

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

We retrospectively analyzed sunitinib outcome as a function of age in metastatic renal cell carcinoma (mRCC) patients.

T E Hutson, R M Bukowski, B I Rini, M E Gore, J M Larkin… in British Journal of Cancer (2014)

Article

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Accurate prediction of outcome for metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy is essential. Most of the available models have been developed in patients treated with cytokines, ...

A Bamias, K Tzannis, B Beuselinck, S Oudard, B Escudier… in British Journal of Cancer (2013)

Article

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (⩾30 months) were investigated in sunitinib-treated patients with metastatic renal cell carcinoma (RCC).

R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson… in British Journal of Cancer (2013)

Article

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symp...

D Cella, B Escudier, B Rini, C Chen, H Bhattacharyya, J Tarazi… in British Journal of Cancer (2013)

Article

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis

Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluati...

G Procopio, J Bellmunt, J Dutcher, S Bracarda, J Knox… in British Journal of Cancer (2013)

Article

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection o...

S Bracarda, T E Hutson, C Porta, R A Figlin, E Calvo… in British Journal of Cancer (2012)

Article

Levels of circulating CD45^dimCD34⁺VEGFR2⁺ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

Predicting the efficacy of antiangiogenic therapy would be of clinical value in patients (pts) with metastatic renal cell carcinoma (mRCC). We tested the hypothesis that circulating endothelial cell (CEC), bon...

F Farace, M Gross-Goupil, E Tournay, M Taylor, N Vimond… in British Journal of Cancer (2011)

Article

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

G H J Mickisch, B Escudier, S Walzer, M Nuijten in British Journal of Cancer (2010)

Article

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have d...

G Mickisch, M Gore, B Escudier, G Procopio, S Walzer… in British Journal of Cancer (2010)

Article

Safety of tracheotomy in neutropenic patients: A retrospective study of 26 consecutive cases

To evaluate the safety of tracheotomy in neutropenic ventilated cancer patients, in terms of infectious and haemorrhagic complications.

F. Blot, G. Nitenberg, M. Guiguet, M. Casetta, S. Antoun… in Intensive Care Medicine (1995)